Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massar Omar

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
American Heart Journal|August 18, 2020
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
American Heart Journal|February 16, 2024
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial programCamilla Fuchs Andersen, Julie Hempel Larsen, Jesper Jensen, et al.
Mayo Clinic Proceedings|December 21, 2023
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction: The INABLE-Training TrialBarry A Borlaug, Katlyn E Koepp, Yogesh N V Reddy, et al.
BMJ Open|February 26, 2026
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysisLuxcia Kugathasan, Massimo Nardone, Marcel Muskiet, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
American Heart Journal|August 18, 2020
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
American Heart Journal|February 16, 2024
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial programCamilla Fuchs Andersen, Julie Hempel Larsen, Jesper Jensen, et al.
Mayo Clinic Proceedings|December 21, 2023
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction: The INABLE-Training TrialBarry A Borlaug, Katlyn E Koepp, Yogesh N V Reddy, et al.
BMJ Open|February 26, 2026
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysisLuxcia Kugathasan, Massimo Nardone, Marcel Muskiet, et al.
Pageof 5